SCN1A -deficient excitatory neuronal networks display mutation-specific phenotypes
Brain · 01.12.2023 · 146 (12) · 5153-5167
DOI: 10.1093/brain/awad245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 19.07.2023. Verfasst von Eline J H van Hugte und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboudumc, 6500 HB Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Epilepsy, Generalized, Seizures, Febrile. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Netherlands Organisation for Health Research and Development, European Joint Programme on Rare Diseases, Dutch epilepsiefonds.
Abstract (Originalsprache)
Dravet syndrome is a severe epileptic encephalopathy, characterized by (febrile) seizures, behavioural problems and developmental delay. Eighty per cent of patients with Dravet syndrome have a mutation in SCN1A, encoding Nav1.1. Milder clinical phenotypes, such as GEFS+ (generalized epilepsy with febrile seizures plus), can also arise from SCN1A mutations. Predicting the clinical phenotypic outcome based on the type of mutation remains challenging, even when the same mutation is inherited within one family. This clinical and genetic heterogeneity adds to the difficulties of predicting disease progression and tailoring the prescription of anti-seizure medication. Understanding the neuropathology of different SCN1A mutations may help to predict the expected clinical phenotypes and inform the selection of best-fit treatments. Initially, the loss of Na+-current in inhibitory neurons was recognized specifically to result in disinhibition and consequently seizure generation. However, the extent to which excitatory neurons contribute to the pathophysiology is currently debated and might depend on the patient clinical phenotype or the specific SCN1A mutation. To examine the genotype-phenotype correlations of SCN1A mutations in relation to excitatory neurons, we investigated a panel of patient-derived excitatory neuronal networks differentiated on multi-electrode arrays. We included patients with different clinical phenotypes, harbouring various SCN1A mutations, along with a family in which the same mutation led to febrile seizures, GEFS+ or Dravet syndrome. We hitherto describe a previously unidentified functional excitatory neuronal network phenotype in the context of epilepsy, which corresponds to seizurogenic network prediction patterns elicited by proconvulsive compounds. We found that excitatory neuronal networks were affected differently, depending on the type of SCN1A mutation, but did not segregate according to clinical severity. Specifically, loss-of-function mutations could be distinguished from missense mutations, and mutations in the pore domain could be distinguished from mutations in the voltage sensing domain. Furthermore, all patients showed aggravated neuronal network responses at febrile temperatures compared with controls. Finally, retrospective drug screening revealed that anti-seizure medication affected GEFS+ patient- but not Dravet patient-derived neuronal networks in a patient-specific and clinically relevant manner. In conclusion, our results indicate a mutation-specific excitatory neuronal network phenotype, which recapitulates the foremost clinically relevant features, providing future opportunities for precision therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Radboudumc, 6500 HB Nijmegen, The Netherlands.
- Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition, and Behaviour, 6500 HB Nijmegen, The Netherlands.
- Department of Epileptology, ACE Kempenhaeghe, 5591 VE Heeze, The Netherlands.
- Department of Informatics, Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genova, 16145 GE Genova, Italy.
- Department of Clinical Neurophysiology, University of Twente, 7522 NB Enschede, The Netherlands.
- Department of Neurology, Stichting Epilepsie Instellingen Nederland (SEIN), 2103 SW Heemstede, The Netherlands.
ORCID-Profile: Eline J H van Hugte, Nael Nadif Kasri
Förderung
- the Netherlands Organisation for Health Research and Development
- European Joint Programme on Rare Diseases
- Dutch epilepsiefonds
- SFARI
Zitieren
APA
van Hugte, E. J. H., Lewerissa, E. I., Wu, K. M., Scheefhals, N., Parodi, G., van Voorst, T. W., Puvogel, S., Kogo, N., Keller, J. M., Frega, M., Schubert, D., Schelhaas, H. J., Verhoeven, J., Majoie, M., van Bokhoven, H., & Nadif Kasri, N. (2023). SCN1A -deficient excitatory neuronal networks display mutation-specific phenotypes. Brain, 146(12), 5153-5167. https://doi.org/10.1093/brain/awad245
Vancouver
van Hugte EJH, Lewerissa EI, Wu KM, Scheefhals N, Parodi G, van Voorst TW, et al. SCN1A -deficient excitatory neuronal networks display mutation-specific phenotypes. Brain. 2023;146(12):5153-5167. doi:10.1093/brain/awad245
BibTeX
@article{vanHugte2023,
author = {van Hugte, Eline J H and Lewerissa, Elly I and Wu, Ka Man and Scheefhals, Nicky and Parodi, Giulia and van Voorst, Torben W and Puvogel, Sofia and Kogo, Naoki and Keller, Jason M and Frega, Monica and Schubert, Dirk and Schelhaas, Helenius J and Verhoeven, Judith and Majoie, Marian and van Bokhoven, Hans and Nadif Kasri, Nael},
title = {SCN1A -deficient excitatory neuronal networks display mutation-specific phenotypes},
journal = {Brain},
year = {2023},
volume = {146},
number = {12},
pages = {5153--5167},
doi = {10.1093/brain/awad245}
}
EUVIMED